SCHEMBL3754458

SCHEMBL3754458

CC(C)Cc1cc(C(=O)Nc2nccs2)n(Cc2ccc(S(C)(=O)=O)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 15/20 0.50
LMNA P02545 1/20 0.48
XBP1 P17861 1/20 0.48
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KCNH2 Q12809 1/20 0.46
SCN3A Q9NY46 2/20 0.45
SCN5A Q14524 1/20 0.45
SCN9A Q15858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3753063 0.91 GCK (0.49) GCKLMNAXBP1HPGDKCNH2
SCHEMBL2660598 0.89 MEN1 (0.60) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL2661512 0.86 LMNA (0.53) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL2662232 0.86 KDM4E (0.50) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL2661308 0.86 MEN1 (0.50) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL2660655 0.85 GCK (0.47) GCKMEN1ALDH1A1HPGDKMT2A
SCHEMBL2661942 0.85 MEN1 (0.48) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL15104194 0.85 GCK (0.46) GCKLMNAXBP1KCNH2
SCHEMBL3743741 0.84 MEN1 (0.49) LMNAXBP1MEN1ALDH1A1HPGD
SCHEMBL2661689 0.83 MEN1 (0.49) GCKLMNAXBP1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP claimed
US-8299115-B2 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2012-10-30 US claimed
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-11-18 US claimed
EP-2155720-B1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LTD (IN) 2013-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292143-A1 PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION GCK, PCK1, GCKR GCK 1/4885LMNA 3790/4885XBP1 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.